期刊
INFECTION AND DRUG RESISTANCE
卷 14, 期 -, 页码 3509-3518出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IDR.S325520
关键词
carbapenem-resistance; extended-spectrum beta-lactamase; multidrug-resistance; beta-lactamase inhibitor; carbapenemase
资金
- Merck Sharp Dohme Corp.
- Beijing Key Clinical Specialty for Laboratory MedicineExcellent Project [ZK201000]
- National Key Research and Development Program of China [2018YFC1200100, 2018YF C1200105]
This study investigated the susceptibility of imipenem/relebactam for infections caused by A. baumannii and P. aeruginosa in China, showing that the drug is effective in treating MDR or imipenem-non-susceptible P. aeruginosa infections but not A. baumannii infections.
Purpose: In recent years, less options are available for treating carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa. The present study investigates the susceptibility rates to imipenem/relebactam for the treatment of intra-abdominal infections (IAIs), respiratory tract infections (RTIs) and urinary tract infections (UTIs) caused by A. baumannii and P. aeruginosa in China. Patients and Methods: A total of 1886 P. aeruginosa and 1889 A. baumannii isolates were collected in 21 centers (7 regions) as a part of the global SMART surveillance program between 2015 and 2018. Antimicrobial susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) recommendations using the broth microdilution methodology at Peking Union Medical College Hospital. Results: For P. aeruginosa, overall susceptibility rates to imipenem/relebactam were 84.2% at a CLSI breakpoint of <= 2 mg/L compared to 55.7% for imipenem. Susceptibility rates of imipenem-non-susceptible P. aeruginosa to imipenem/relebactam were 64.4% and for multidrug-resistance (MDR) P. aeruginosa susceptibility rates were increased from 25.2% for imipenem to 65.8% for imipenem/relebactam. The susceptibilities of imipenem-nonsusceptible and MDR P. aeruginosa strains were similarly restored by imipenem/relebactam in non-ICU and ICU wards. The rate of imipenem-non-susceptibilities A. baumannii isolates was 79.0%, whereas the MDR rate was 81.9%. Relebactam did not change the susceptibilities of imipenem-non susceptible or MDR A. baumannii isolates. Conclusion: Imipenem/relebactam provides a therapy option to treat infections caused by MDR or imipenem-non-susceptible P. aeruginosa but not A. baumannii infections in China.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据